Mergers & Acquisitions ·
Addex Therapeutics regains full global rights to GABAB assets from Indivior
ADXNAddex Therapeutics Ltd.
Addex Therapeutics regained full global rights to all GABAB positive allosteric modulator assets from Indivior following the latter's rationalization of R&D activities and planned merger with Supernus Pharmaceuticals. This termination grants Addex ownership of a returned development candidate for substance use disorders, which has completed IND enabling studies, alongside its proprietary chronic cough program. The company now holds one of the broadest portfolios targeting GABAB receptor biology, with potential applications in pain, overactive bladder, and neurodevelopmental disorders. Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders.